Sahajanand Medical Technologies Ltd IPOSMT

Initial public offering of 13,822,116 equity shares of face value of Re. 1 each ("Equity Shares") of Sahajanand Medical Technologies Limited (the "Company" or the "Issuer") for cash at a price of Rs. 344 per equity share (Including a share Premium of Rs. 343 per equity share) (the "Offer Price") aggregating to Rs. 475.48 Crores through an offer for sale (the "Offer"), consisting of 2,700,000 equity shares of face value of Re. 1 each aggregating to Rs. 92.88 Crores by Shree Hari Trust, 2,000,000 equity shares of face value of Re. 1 each aggregating to Rs. 68.8 Crores by Dhirajkumar Savjibhai Vasoya, 6,479,063 equity shares of face value of Re. 1 each aggregating to Rs. 222.88 Crores by Samara Capital Markets Holding Limited, 1,307,875 equity shares of face value of Re. 1 each aggregating to Rs. 44.99 Crores by Kotak Pre-IPO Opportunities Fund, and 1,335,178 equity shares of face value of Re. 1 each aggregating to Rs. 45.93 Crores by Nhpea Sparkle Holding B.V. (Collectively, the "Selling Shareholders" and such equity shares, the "Offered Shares"). The offer included a reservation of up to 250,000 equity shares of face value of Re. 1 each (Constituting 0.25% of the post issue paid up equity share capital of the Company) aggregating up to Rs. 8.6 Crores for subscription by eligible employees (the "Employee Reservation Portion"). The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The offer and the net offer will constituted 13.60% and 13.57% of the post-offer paid-up equity share capital, respectively. Price Band: Rs. 344 per equity share of face value of Rs. 1 each. The floor price is 344 times the face value of the equity shares. Bids can made for a minimum of 43 equity shares of face value of Rs. 1 each and in multiples of 43 equity shares of face value of Rs. 1 each thereafter.

Sahajanand Medical Technologies Limited was initially formed as a Partnership Firm named M/s Sahajanand Vacular Technoventions' pursuant to a Partnership Deed dated on October 25, 1999. Subsequently, the Partnership Firm was reconstituted and name of the Firm was changed to M/s Sahajanand Medical Technologies' dated September 30, 2001. The Partnership Firm converted into a Joint Stock Company and got registered as a Private Limited Company with the name Sahajanand Medical Technologies Private Limited' on October 18, 2001. Consequently, the Company converted into a Public Company on April 27, 2021 and the name was changed to Sahajanand Medical Technologies Limited', vide a fresh Certificate of Incorporation on May 7, 2021 issued by the RoC, Gujarat. The Company is a leading medical devices company that researches, designs, develops, manufactures and markets vascular devices globally. It differentiate product offering by providing customers with high quality products at market appropriate prices supported by strong clinical data. It has a direct and distributor sales presence in more than 69 countries including direct presence in countries such as Germany, Poland, Spain, France, UK and Brazil. Presently, the Company offer products used in Interventional Cardiology, i.e., devices used for the treatment of blockages in heart vessels (coronary artery disease), such as coronary stents and catheters; Structural Heart Therapy, i.e., devices used for treatment of abnormalities in the tissues, walls, and valves of the heart, such as transcatheter aortic valve implants (TAVI) and occluders; and Peripheral Intervention, i.e., devices used for treatment of blockages in the blood vessels other than those of the heart, such as renal stents. Apart from these, the Company operate 3 manufacturing facilities in India located at Surat and Bengaluru; where it manufacture products for interventional cardiology and peripheral intervention, and one overseas facility at Nonthaburi in Thailand where it manufacture products for structural heart therapy. The Company was founded by Mr. Dhirajlal Kotadia in making critical life-saving products accessible to the masses that ultimately led him to establish the Company in 2001. Under Mr. Kotadia's leadership, the Company has been a pioneer in the vascular devices industry, having introduced the biodegradable polymer DES in 2005, which launched lowest strut thickness stents with a 60-micron thickness. The Company launched 'Renofit', a balloon expandable cobalt chromium renal and biliary stent system in 2015. The portfolio is led by flagship coronary stent, Supraflex Cruz. In 2016, the Company initiated 'TALENT' ,a randomized clinical trial that compared the performance of stent, Supraflex, against that of a global leading stent manufacturer. In 2018, it launched Supraflex Cruz', which is considered as the most deliverable stent. It got into a strategic partnership with Cardinal Health Medical Products India Limited for exclusive distribution of Cordis products and gained access to the cardio accessories and endovascular segments. The Company started marketing products in Germany and Poland in 2019. In June 2019, it acquired Imex Clinic Salud S.L, which was a distributor in Spain. In September 2019, it acquired Zarek, a sales and marketing company with a portfolio of interventional cardiology and endovascular products based in Brazil, which was also their distributor. In May 2020, it expanded product portfolio and got into structural heart therapy segment by acquiring Vascular Concepts and Vascular Innovations. As of March 31, 2021, Company has a direct operations in 10 countries and distributor sales presence in more than 59 countries through a network of 67 distributors. The Company is planning to come out with an Initial Public Offering aggregating upto Rs. 1500 crore Equity Shares which comprises by raising capital of up to Rs. 410.33 crore through Fresh Issue of Equity Shares and an Offer for Sale of up to Rs 1,089.67 crore Equity Shares.